Abiopharma

🔍 Graul Regina Margaret (Executive)

Company: Cyclerion Therapeutics, Inc. (CYCN)

Report Date: 2026-08-14

Detailed Transactions and Holdings:

• Acquired 55,849 shares of Common Stock, no par value at $3.3 per share (Direct)
  Date: 2026-08-14 | Code: M | equity_swap_involved: false | shares_owned_after: 156,152.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 48,629 shares of Common Stock, no par value at $3.79 per share (Direct)
  Date: 2026-08-14 | Code: F | equity_swap_involved: false | shares_owned_after: 107,523.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 55,849 shares of Option to Purchase at $3.3 per share (Derivative)
  Date: 2026-08-14 | Code: M | Expires: 2034-08-03 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1

Footnotes:

• F1: The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person.
• F2: The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cashless exercise, forfeiting options to purchase 48,629 shares as payment to the Issuer for the full exercise price.
• REMARKS: President and Chief Executive Officer